Log in

NASDAQ:LIFE - aTyr Pharma Stock Price, Forecast & News

-0.17 (-4.06 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
Now: $4.02
50-Day Range
MA: $5.16
52-Week Range
Now: $4.02
Volume190,584 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryLife Sciences Tools & Services
Current SymbolNASDAQ:LIFE



Sales & Book Value

Annual SalesN/A



Next Earnings Date3/23/2020 (Estimated)

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.43) by $0.04. The biotechnology company had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.06 million. View aTyr Pharma's Earnings History.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for aTyr Pharma.

What price target have analysts set for LIFE?

3 analysts have issued twelve-month target prices for aTyr Pharma's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate aTyr Pharma's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 49.3% from the stock's current price. View Analyst Price Targets for aTyr Pharma.

What is the consensus analysts' recommendation for aTyr Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.

Has aTyr Pharma been receiving favorable news coverage?

News stories about LIFE stock have trended neutral on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. aTyr Pharma earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for aTyr Pharma.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,700 shares, an increase of 91.4% from the December 31st total of 3,500 shares. Based on an average daily volume of 218,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.2% of the shares of the stock are sold short. View aTyr Pharma's Current Options Chain.

Who are some of aTyr Pharma's key competitors?

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), Gilead Sciences (GILD), QUALCOMM (QCOM), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL) and Idera Pharmaceuticals (IDRA).

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:
  • Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
  • Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)
  • Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
  • Dr. David J. King, Scientific Consultant (Age 60)
  • Xiang-Lei Yang Ph.D., Founder

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.14%), First Republic Investment Management Inc. (0.58%) and Virtu Financial LLC (0.29%). Company insiders that own aTyr Pharma stock include Ecor1 Capital Fund Qualified,, Jill Marie Broadfoot, John Mendlein, Nancy Krueger and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.

Which institutional investors are buying aTyr Pharma stock?

LIFE stock was acquired by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., Virtu Financial LLC and Renaissance Technologies LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $4.02.

MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  795
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel